<DOC>
	<DOCNO>NCT01724814</DOCNO>
	<brief_summary>Study Design : Part 1.Randomized , double-blind , placebo-controlled , escalate single-dose design Healthy volunteer Part 2.Open , sequential , two-period , single dose study type 1 diabetes Part 3.Open , sequential , two-period , single dose study type 2 diabetes</brief_summary>
	<brief_title>A First-in-human Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics HM12460A</brief_title>
	<detailed_description>The principle objective study assess safety tolerability explore pharmacokinetic ( PK ) pharmacodynamic ( PD ) parameter single dose novel very-long act insulin formulation ( HM12460A ) comparison single dose human Neutral Protamine Hagedorn ( NPH ) healthy volunteer ( part 1 ) , subject type 1 diabetes ( part 2 ) subject type 2 diabetes ( part 3 ) . The study incorporate adaptive element provide PK PD data . The dose HM12460A administer subject type 1 diabetes type 2 diabetes guide PK data part 1 study ; PD assessment HM12460A subject diabetes also inform knowledge PK gain healthy volunteer study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Healthy subject Age ≥18 ≤70 year Nonobese ; body mass index 18.0 30.0 kg/m2 inclusive . Considered generally healthy upon completion medical history , physical examination biochemical investigation judge Investigator . Nonsmoker , light smoker , define &lt; 15 cigarettes/day able abstain smoke confinement period . Females must nonpregnant nonlactating , either surgically sterile ( e.g. , tubal occlusion , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) postmenopausal &gt; 12 month . Males must surgically sterile , abstinent engage sexual relation childbearing potential , subject must use acceptable contraceptive method period 60 day last dose Study Drug . Signed date informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) . Previous participation trial clinical trial within last 3 month . Clinically significant abnormal hematology biochemistry screen test , judge Investigator . In particular , healthy subject liver enzymes upper limit normal range subject diabetes elevate liver enzymes ( AST ALT &gt; 2 time upper limit normal ) impair renal function ( elevate serum creatinine value upper limit normal ) exclude . History illness , opinion Investigator , might confound result trial pose risk administer trial drug subject . In particular , subject significant cardiovascular disease , anemia ( hemoglobin low limit normal ) hemoglobinopathy allow enter trial . Clinically significant abnormal ECG screening , judge Investigator . History alcohol abuse . Any positive reaction drug abuse . Hepatitis B C HIV positive . Use prescription drug within 3 week precede first dose insulin , except medication deem acceptable per protocol specific list concomitant medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>